Redeye provides an update on Saniona. In Q3, Saniona expectedly received the USD42.
Redeye comments on the USTR’s confirmation that the Section 301 tariff exemption for computer cases ...
Redeye provides a summary of Paxman’s CMD. The event offered no material surprises and introduced li...
Redsense Medical fortsätter att växa trots valutamotvind, med en stark Q3-förbättring både i omsättn...
* Strategic pivot into the SOFC market * Rights issue of ~SEK 87.
Redeye comments on the new orphan drug designation for the treatment of Osteogenesis Imperfecta from...
Redeye returns with an updated view of Egetis Therapeutics following the Q3 report and the recent Re...
* European Commission drafts proposal for non-renewal of Selektope * Limited impact on near-term est...
Redeye provides an in-depth update on AcouSort following the company’s Q3 report.
Redeye visited Cheffelo’s Mölnlycke facility, where Linas Matkasse’s meal kits are produced.
Xplora reported strong demand for its products and subscriptions in the Q3 report, and it reported g...
Case Group rapporterade sitt starkaste kvartal någonsin med stark tillväxt, stabila kapitalflöden oc...
Redeye comments on Iconovo’s announcement of a directed share issue and a fully guaranteed rights is...
Redeye notes that Xplora’s third-quarter report marks a distinct inflection in profitability, with a...
* Q3: high GM, but soft device sales and ARPU * Doro conversion rate 25% in D2C channels (13% in Q2)...
